Noninvasive assessment of pancreatic β-cell function in vivo with manganese-enhanced magnetic resonance imaging

Patrick F. Antkowiak, Sarah A. Tersey, Jeffrey D. Carter, Moriel H. Vandsburger, Jerry L. Nadler, Frederick H. Epstein, Raghu Mirmira

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Loss of β-cell function in type 1 and type 2 diabetes leads to metabolic dysregulation and inability to maintain normoglycemia. Noninvasive imaging of β-cell function in vivo would therefore provide a valuable diagnostic and research tool for quantifying progression to diabetes and response to therapeutic intervention. Because manganese (Mn2+) is a longitudinal relaxation time (T1)-shortening magnetic resonance imaging (MRI) contrast agent that enters cells such as pancreatic β-cells through voltage-gated calcium channels, we hypothesized that Mn2+-enhanced MRI of the pancreas after glucose infusion would allow for noninvasive detection of β-cell function in vivo. To test this hypothesis, we administered glucose and saline challenges intravenously to normal mice and mice given high or low doses of streptozotocin (STZ) to induce diabetes. Serial inversion recovery MRI was subsequently performed after Mn2+ injection to probe Mn2+ accumulation in the pancreas. Time-intensity curves of the pancreas (normalized to the liver) fit to a sigmoid function showed a 51% increase in signal plateau height after glucose stimulation relative to saline (P < 0.01) in normal mice. In diabetic mice given a high dose of STZ, only a 9% increase in plateau signal intensity was observed after glucose challenge (P = not significant); in mice given a low dose of STZ, a 20% increase in plateau signal intensity was seen after glucose challenge (P = 0.02). Consistent with these imaging findings, the pancreatic insulin content of high- and low-dose STZ diabetic mice was reduced about 20-fold and 10-fold, respectively, compared with normal mice. We conclude that Mn2+-enhanced MRI demonstrates excellent potential as a means for noninvasively monitoring β-cell function in vivo and may have the sensitivity to detect progressive decreases in function that occur in the diabetic disease process.

Original languageEnglish
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume296
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Manganese
Magnetic Resonance Imaging
Streptozocin
Glucose
Pancreas
Sigmoid Colon
Calcium Channels
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Contrast Media
Insulin
Injections
Liver
Research

Keywords

  • Diabetes
  • Islet

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism

Cite this

Noninvasive assessment of pancreatic β-cell function in vivo with manganese-enhanced magnetic resonance imaging. / Antkowiak, Patrick F.; Tersey, Sarah A.; Carter, Jeffrey D.; Vandsburger, Moriel H.; Nadler, Jerry L.; Epstein, Frederick H.; Mirmira, Raghu.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 296, No. 3, 03.2009.

Research output: Contribution to journalArticle

Antkowiak, Patrick F. ; Tersey, Sarah A. ; Carter, Jeffrey D. ; Vandsburger, Moriel H. ; Nadler, Jerry L. ; Epstein, Frederick H. ; Mirmira, Raghu. / Noninvasive assessment of pancreatic β-cell function in vivo with manganese-enhanced magnetic resonance imaging. In: American Journal of Physiology - Endocrinology and Metabolism. 2009 ; Vol. 296, No. 3.
@article{2675a7a637bf475784433783063ec383,
title = "Noninvasive assessment of pancreatic β-cell function in vivo with manganese-enhanced magnetic resonance imaging",
abstract = "Loss of β-cell function in type 1 and type 2 diabetes leads to metabolic dysregulation and inability to maintain normoglycemia. Noninvasive imaging of β-cell function in vivo would therefore provide a valuable diagnostic and research tool for quantifying progression to diabetes and response to therapeutic intervention. Because manganese (Mn2+) is a longitudinal relaxation time (T1)-shortening magnetic resonance imaging (MRI) contrast agent that enters cells such as pancreatic β-cells through voltage-gated calcium channels, we hypothesized that Mn2+-enhanced MRI of the pancreas after glucose infusion would allow for noninvasive detection of β-cell function in vivo. To test this hypothesis, we administered glucose and saline challenges intravenously to normal mice and mice given high or low doses of streptozotocin (STZ) to induce diabetes. Serial inversion recovery MRI was subsequently performed after Mn2+ injection to probe Mn2+ accumulation in the pancreas. Time-intensity curves of the pancreas (normalized to the liver) fit to a sigmoid function showed a 51{\%} increase in signal plateau height after glucose stimulation relative to saline (P < 0.01) in normal mice. In diabetic mice given a high dose of STZ, only a 9{\%} increase in plateau signal intensity was observed after glucose challenge (P = not significant); in mice given a low dose of STZ, a 20{\%} increase in plateau signal intensity was seen after glucose challenge (P = 0.02). Consistent with these imaging findings, the pancreatic insulin content of high- and low-dose STZ diabetic mice was reduced about 20-fold and 10-fold, respectively, compared with normal mice. We conclude that Mn2+-enhanced MRI demonstrates excellent potential as a means for noninvasively monitoring β-cell function in vivo and may have the sensitivity to detect progressive decreases in function that occur in the diabetic disease process.",
keywords = "Diabetes, Islet",
author = "Antkowiak, {Patrick F.} and Tersey, {Sarah A.} and Carter, {Jeffrey D.} and Vandsburger, {Moriel H.} and Nadler, {Jerry L.} and Epstein, {Frederick H.} and Raghu Mirmira",
year = "2009",
month = "3",
doi = "10.1152/ajpendo.90336.2008",
language = "English",
volume = "296",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Noninvasive assessment of pancreatic β-cell function in vivo with manganese-enhanced magnetic resonance imaging

AU - Antkowiak, Patrick F.

AU - Tersey, Sarah A.

AU - Carter, Jeffrey D.

AU - Vandsburger, Moriel H.

AU - Nadler, Jerry L.

AU - Epstein, Frederick H.

AU - Mirmira, Raghu

PY - 2009/3

Y1 - 2009/3

N2 - Loss of β-cell function in type 1 and type 2 diabetes leads to metabolic dysregulation and inability to maintain normoglycemia. Noninvasive imaging of β-cell function in vivo would therefore provide a valuable diagnostic and research tool for quantifying progression to diabetes and response to therapeutic intervention. Because manganese (Mn2+) is a longitudinal relaxation time (T1)-shortening magnetic resonance imaging (MRI) contrast agent that enters cells such as pancreatic β-cells through voltage-gated calcium channels, we hypothesized that Mn2+-enhanced MRI of the pancreas after glucose infusion would allow for noninvasive detection of β-cell function in vivo. To test this hypothesis, we administered glucose and saline challenges intravenously to normal mice and mice given high or low doses of streptozotocin (STZ) to induce diabetes. Serial inversion recovery MRI was subsequently performed after Mn2+ injection to probe Mn2+ accumulation in the pancreas. Time-intensity curves of the pancreas (normalized to the liver) fit to a sigmoid function showed a 51% increase in signal plateau height after glucose stimulation relative to saline (P < 0.01) in normal mice. In diabetic mice given a high dose of STZ, only a 9% increase in plateau signal intensity was observed after glucose challenge (P = not significant); in mice given a low dose of STZ, a 20% increase in plateau signal intensity was seen after glucose challenge (P = 0.02). Consistent with these imaging findings, the pancreatic insulin content of high- and low-dose STZ diabetic mice was reduced about 20-fold and 10-fold, respectively, compared with normal mice. We conclude that Mn2+-enhanced MRI demonstrates excellent potential as a means for noninvasively monitoring β-cell function in vivo and may have the sensitivity to detect progressive decreases in function that occur in the diabetic disease process.

AB - Loss of β-cell function in type 1 and type 2 diabetes leads to metabolic dysregulation and inability to maintain normoglycemia. Noninvasive imaging of β-cell function in vivo would therefore provide a valuable diagnostic and research tool for quantifying progression to diabetes and response to therapeutic intervention. Because manganese (Mn2+) is a longitudinal relaxation time (T1)-shortening magnetic resonance imaging (MRI) contrast agent that enters cells such as pancreatic β-cells through voltage-gated calcium channels, we hypothesized that Mn2+-enhanced MRI of the pancreas after glucose infusion would allow for noninvasive detection of β-cell function in vivo. To test this hypothesis, we administered glucose and saline challenges intravenously to normal mice and mice given high or low doses of streptozotocin (STZ) to induce diabetes. Serial inversion recovery MRI was subsequently performed after Mn2+ injection to probe Mn2+ accumulation in the pancreas. Time-intensity curves of the pancreas (normalized to the liver) fit to a sigmoid function showed a 51% increase in signal plateau height after glucose stimulation relative to saline (P < 0.01) in normal mice. In diabetic mice given a high dose of STZ, only a 9% increase in plateau signal intensity was observed after glucose challenge (P = not significant); in mice given a low dose of STZ, a 20% increase in plateau signal intensity was seen after glucose challenge (P = 0.02). Consistent with these imaging findings, the pancreatic insulin content of high- and low-dose STZ diabetic mice was reduced about 20-fold and 10-fold, respectively, compared with normal mice. We conclude that Mn2+-enhanced MRI demonstrates excellent potential as a means for noninvasively monitoring β-cell function in vivo and may have the sensitivity to detect progressive decreases in function that occur in the diabetic disease process.

KW - Diabetes

KW - Islet

UR - http://www.scopus.com/inward/record.url?scp=64749099588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749099588&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.90336.2008

DO - 10.1152/ajpendo.90336.2008

M3 - Article

C2 - 19116376

AN - SCOPUS:64749099588

VL - 296

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 3

ER -